|
1
|
Genden EM, Ferlito A, Silver CE, Jacobson
AS, Werner JA, Suárez C, Leemans CR, Bradley PJ and Rinaldo A:
Evolution of the management of laryngeal cancer. Oral Oncol.
43:431–439. 2007. View Article : Google Scholar
|
|
2
|
Marioni G, Marchese-Ragona R, Cartei G,
Marchesex F and Staffieri A: Current opinion in diagnosis and
treatment of laryngeal carcinoma. Cancer Treat Rev. 32:504–515.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zheng Y, Liu M, Li M, Zhang J, Ge J, Sun Y
and Tian L: The influence of the 'patient-to-patient model' on
swallowing problems in patients with supraglottic laryngeal cancer.
ORL J Otorhinolaryngol Relat Spec. 76:171–177. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jenckel F and Knecht R: State of the art
in the treatment of laryngeal cancer. Anticancer Res. 33:4701–4710.
2013.PubMed/NCBI
|
|
5
|
Ma J, Liu Y, Huang XL, Zhang ZY, Myers JN,
Neskey DM and Zhong LP: Induction chemotherapy decreases the rate
of distant metastasis in patients with head and neck squamous cell
carcinoma but does not improve survival or locoregional control: A
meta-analysis. Oral Oncol. 48:1076–1084. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nohata N, Hanazawa T, Kinoshita T, Okamoto
Y and Seki N: MicroRNAs function as tumor suppressors or oncogenes:
Aberrant expression of microRNAs in head and neck squamous cell
carcinoma. Auris Nasus Larynx. 40:143–149. 2013. View Article : Google Scholar
|
|
7
|
Cao P, Zhou L, Zhang J, Zheng F, Wang H,
Ma D and Tian J: Comprehensive expression profiling of microRNAs in
laryngeal squamous cell carcinoma. Head Neck. 35:720–728. 2013.
View Article : Google Scholar
|
|
8
|
Ren J, Zhu D, Liu M, Sun Y and Tian L:
Downregulation of miR-21 modulates Ras expression to promote
apoptosis and suppress invasion of Laryngeal squamous cell
carcinoma. Eur J Cancer. 46:3409–3416. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sun X, Liu B, Zhao XD, Wang LY and Ji WY:
MicroRNA-221 accelerates the proliferation of laryngeal cancer cell
line Hep-2 by suppressing Apaf-1. Oncol Rep. 33:1221–1226.
2015.PubMed/NCBI
|
|
10
|
Zhu W, Zhao Y, Xu Y, Sun Y, Wang Z, Yuan W
and Du Z: Dissection of protein interactomics highlights microRNA
synergy. PLoS One. 8:e633422013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li D, Feng J, Wu T, Wang Y, Sun Y, Ren J
and Liu M: Long intergenic noncoding RNA HOTAIR is overexpressed
and regulates PTEN methylation in laryngeal squamous cell
carcinoma. Am J Pathol. 182:64–70. 2013. View Article : Google Scholar
|
|
12
|
Meng F, Henson R, Wehbe-Janek H, Ghoshal
K, Jacob ST and Patel T: MicroRNA-21 regulates expression of the
PTEN tumor suppressor gene in human hepatocellular cancer.
Gastroenterology. 133:647–658. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Garofalo M, Di Leva G, Romano G, Nuovo G,
Suh SS, Ngankeu A, Taccioli C, Pichiorri F, Alder H, Secchiero P,
et al: miR-221&222 regulate TRAIL resistance and enhance
tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell.
16:498–509. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li R, Wang R, Zhai R and Dong Z: Targeted
inhibition of mammalian target of rapamycin (mTOR) signaling
pathway inhibits proliferation and induces apoptosis of laryngeal
carcinoma cells in vitro. Tumori. 97:781–786. 2011.
|
|
15
|
Paez J and Sellers WR: PI3K/PTEN/Akt
pathway. A critical mediator of oncogenic signaling. Cancer Treat
Res. 115:145–167. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yu C, Liu Y, Tan H, Li G, Su Z, Ren S, Zhu
G, Tian Y, Qiu Y and Zhang X: Metadherin regulates metastasis of
squamous cell carcinoma of the head and neck via Akt signalling
pathway-mediated epithelial-mesenchymal transition. Cancer Lett.
343:258–267. 2014. View Article : Google Scholar
|
|
17
|
Abraham AG and O'Neill E:
PI3K/Akt-mediated regulation of p53 in cancer. Biochem Soc Trans.
42:798–803. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Suzuki HI, Yamagata K, Sugimoto K, Iwamoto
T, Kato S and Miyazono K: Modulation of microRNA processing by p53.
Nature. 460:529–533. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar
|
|
20
|
Garzon R, Calin GA and Croce CM: MicroRNAs
in Cancer. Annu Rev Med. 60:167–179. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Garzon R, Marcucci G and Croce CM:
Targeting microRNAs in cancer: Rationale, strategies and
challenges. Nat Rev Drug Discov. 9:775–789. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sethi N, Wright A, Wood H and Rabbitts P:
MicroRNAs and head and neck cancer: Reviewing the first decade of
research. Eur J Cancer. 50:2619–2635. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Singh S, Narang AS and Mahato RI:
Subcellular fate and off-target effects of siRNA, shRNA and miRNA.
Pharm Res. 28:2996–3015. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xu J, Li CX, Li YS, Lv JY, Ma Y, Shao TT,
Xu LD, Wang YY, Du L, Zhang YP, et al: MiRNA-miRNA synergistic
network: Construction via co-regulating functional modules and
disease miRNA topological features. Nucleic Acids Res. 39:825–836.
2011. View Article : Google Scholar :
|
|
25
|
Dong CG, Wu WK, Feng SY, Wang XJ, Shao JF
and Qiao J: Co-inhibition of microRNA-10b and microRNA-21 exerts
synergistic inhibition on the proliferation and invasion of human
glioma cells. Int J Oncol. 41:1005–1012. 2012.PubMed/NCBI
|
|
26
|
Noguchi S, Yasui Y, Iwasaki J, Kumazaki M,
Yamada N, Naito S and Akao Y: Replacement treatment with
microRNA-143 and -145 induces synergistic inhibition of the growth
of human bladder cancer cells by regulating PI3K/Akt and MAPK
signaling pathways. Cancer Lett. 328:353–361. 2013. View Article : Google Scholar
|
